<?xml version="1.0" encoding="UTF-8"?>
<p id="par0085">Seroneutralization assays: Thirty-two studies identifying evidence of JE using neutralization assays (see 
 <xref rid="tbl0025" ref-type="table">Table 5</xref>) are included, of which 15 clearly performed tests on acute and convalescent sera, indicating seroconversion (
 <xref rid="bib0140" ref-type="bibr">Cardosa et al., 1991</xref>, 
 <xref rid="bib0575" ref-type="bibr">Peiris et al., 1992</xref>, 
 <xref rid="bib0170" ref-type="bibr">CDC, 2005</xref>, 
 <xref rid="bib0175" ref-type="bibr">CDC, 2011</xref>, 
 <xref rid="bib0025" ref-type="bibr">Anga et al., 2010</xref>, 
 <xref rid="bib0030" ref-type="bibr">Anukumar et al., 2014a</xref>, 
 <xref rid="bib0335" ref-type="bibr">Hennessy et al., 1996</xref>, 
 <xref rid="bib0355" ref-type="bibr">Hossain et al., 2010</xref>, 
 <xref rid="bib0450" ref-type="bibr">Langevin et al., 2012a</xref>, 
 <xref rid="bib0465" ref-type="bibr">Lee et al., 2012</xref>, 
 <xref rid="bib0480" ref-type="bibr">Li et al., 2016</xref>, 
 <xref rid="bib0550" ref-type="bibr">Olsen et al., 2010</xref>, 
 <xref rid="bib0555" ref-type="bibr">Ompusunggu et al., 2008</xref>, 
 <xref rid="bib0665" ref-type="bibr">Saito et al., 1999a</xref>, 
 <xref rid="bib0715" ref-type="bibr">Solomon et al., 2008b</xref>, 
 <xref rid="bib0730" ref-type="bibr">Sunwoo et al., 2016</xref>, 
 <xref rid="bib0760" ref-type="bibr">Touch et al., 2009a</xref>). These were largely PRNT (14 articles) and/or a microtiter modification in a 96-well plate (4 articles). Three studies performed focus-reduction seroneutralization tests (FRNT), a high-throughput modification of the PRNT involving 96-well plates and an immunocalorimetric assay for end-point determination. Other studies did not describe their methods in detail or cite references to support them. Eleven reported JEV strain used (
 <xref rid="bib0650" ref-type="bibr">Sabin (1947)</xref>; 
 <xref rid="bib0140" ref-type="bibr">Cardosa et al., 1991</xref>; 
 <xref rid="bib0480" ref-type="bibr">Li et al. (2016)</xref>; 
 <xref rid="bib0680" ref-type="bibr">Saito et al. (2015)</xref>; 
 <xref rid="bib0065" ref-type="bibr">Benenson et al., 1975a</xref>; 
 <xref rid="bib0610" ref-type="bibr">Ravi et al., 2009</xref>; 
 <xref rid="bib0210" ref-type="bibr">Desai et al. (1997a)</xref>; 
 <xref rid="bib0035" ref-type="bibr">Anukumar et al., 2014b</xref>; 
 <xref rid="bib0440" ref-type="bibr">Kyaw et al., 2019</xref>; 
 <xref rid="bib0660" ref-type="bibr">Sabin et al., 1947b</xref>; 
 <xref rid="bib0090" ref-type="bibr">Borah et al., 2011b</xref>): they were all genotype 3 viruses, except for one that reported the use of genotype 1 and 3 strains to enable neutralization-based genotype differentiation (
 <xref rid="bib0680" ref-type="bibr">Saito et al., 2015</xref>). Five studies indicated JEV inoculating dose: the end-point was identified by visual inspection of the cytopathic effect (CPE), staining, or immunofluorescence. All reports appeared to use two-fold dilutions of serum samples, between 1:10 to 1:640 or higher. In terms of quality control, three studies detailed other viruses used, and the use of replicates. Five studies (
 <xref rid="bib0650" ref-type="bibr">Sabin (1947)</xref>; 
 <xref rid="bib0140" ref-type="bibr">Cardosa et al., 1991</xref>; 
 <xref rid="bib0610" ref-type="bibr">Ravi et al., 2009</xref>; 
 <xref rid="bib0035" ref-type="bibr">Anukumar et al., 2014b</xref>; 
 <xref rid="bib0660" ref-type="bibr">Sabin et al., 1947b</xref>) included the use of other flaviviruses such as dengue viruses, West Nile virus, or yellow fever virus.
</p>
